Pre-clinical treatment with the SHH inhibitor IPI-926, a compound presented by Olive et al. as a drug that in vivo depleted the tumor-associated stromal tissue, i.e., decreased α-SMA+ myofibroblast proliferation and profoundly modified the tumor vasculature, was responsible for enhanced intratumoral chemotherapy delivery [97]. Here, SHH is linked to neoplasm.